A new study has concluded that the more Covid mRNA shots a person receives, the more likely they are to contract COVID-19.
Dr. Nabin Shrestha and his team conducted an analysis of data from Cleveland Clinic employees.
The researchers reported that they found that the likelihood of a person contracting Covid increased each time they received a dose of the vaccine.
People who received two or more doses were at higher risk of COVID-19, they noted.
The risk of contracting COVID-19 was 1.5 times higher for those who received two doses and 1.95 times higher for those who received three doses, the researchers found
Those who received three or more doses were 2.5 times more likely to contract the virus.
The higher risk was compared to people who received zero or one dose of a vaccine.
Even after adjusting for variables, the elevated risk remained.
“The exact reason for this finding is not clear,” the researchers said in the paper, which was released as a preprint.
“It is possible that this may be related to the fact that vaccine-induced immunity is weaker and less durable than natural immunity.
“So, although somewhat protective in the short term, vaccination may increase risk of future infection.”
Dr. Robert Malone, a vaccine researcher and inventor of mRNA technology, told The Epoch Times that the paper served as “another acknowledgment that the products are not effective or are at very low effectiveness and are contributing to negative effectiveness [down the line].”
Malone, who was not involved in the paper, noted that the researchers did not study vaccine safety among the employee population.
The COVID-19 vaccines can cause a number of side effects, including fatal heart inflammation, according to the literature and death records.
Earlier studies and data have also suggested that people with more vaccine doses are more susceptible to COVID-19 infection, including previous papers from the Cleveland Clinic scientists and a study from Iceland.
The U.S. Centers for Disease Control and Prevention (CDC), which has repeatedly declined requests to comment on outside research, recommends virtually all people aged 6 months and older receive one of the currently available COVID-19 vaccines, regardless of how many shots they’ve received.
However, a meeting later in May is set to discuss whether to update the vaccine formulations to improve protection.
CDC scientists said in a paper published in February in the agency’s weekly report that the latest version of the vaccines, a monovalent targeting the XBB.1.5 subvariant, provided 49 percent effectiveness between 60 and 119 days later when the JN.1 virus strain was dominant.
Supplementary data, however, showed that people aged 50 and older who received the previous bivalent version were more susceptible to symptomatic infection.
The new study disclosed no conflicts of interest and acknowledged at least five limitations, including how they used a proxy for infection with JN.1.
Another study, released ahead of peer review in April, estimated the effectiveness of Pfizer’s updated vaccine as 32 percent against hospitalization from late 2023 through early 2024.
The research was conducted by scientists from multiple institutions, including the U.S. Department of Veterans Affairs and Pfizer, many authors reported conflicts of interest, and some of the funding came from Pfizer.
People’s immune systems being trained to react to older virus strains at the expense of protection against newer variants is one theory for why the vaccinated might be more prone to infection.
“Multiple vaccine doses may have the effect of antibody-dependent enhancement or ‘original antigenic sin,’ which increase the infection response disproportionally to antibodies generated from the first vaccine dose, rather than from the current vaccine or the current infection, making the antibody response less effective,” Dr. Harvey Risch, professor emeritus of epidemiology at the Yale School of Public Health said after reviewing the paper.
Dr. Shrestha and the Cleveland Clinic researchers aimed to analyze the effectiveness of the XBB.1.5 shots against JN.1, which displaced XBB.1.5 before the end of 2023.
To do so, they analyzed the incidence of COVID-19 among Cleveland Clinic employees from Dec. 31, 2023, to April 22, 2024.
Among approximately 47,500 employees included in the study, 838 tested positive for COVID-19 during that period.
Unadjusted data showed no difference between people who received one of the updated shots and people who didn’t, but after adjusting for age and other factors, the researchers estimated the shots provided 23 percent effectiveness against infection.
Federal and global guidelines consider vaccines ineffective if they provide under 50 percent shielding.
The number of severe illnesses among the study population was too small to estimate effectiveness against severe illness, the researchers said.
Listed limitations included the inability to separate symptomatic and asymptomatic infections.
No conflicts of interest were reported and authors said they received no funding.
No comments:
Post a Comment